DaShenLin Pharmaceutical Group Co

DaShenLin Pharmaceutical Group Co Inventory

The Inventory of DaShenLin Pharmaceutical Group Co (603233.SS) as of Oct 31, 2026 is 4.14 B CNY. In the previous year, Inventory was 4.13 B CNY — a change of 0.32% (higher).

Inventory

4.14 BCNY

YoY

0.32%

Last updated:

Inventory of DaShenLin Pharmaceutical Group Co is 2025 4.14 B CNY. Inventory of DaShenLin Pharmaceutical Group Co was 2024 4.13 B CNY. It decreases by 0.32% higher compared to the previous year.

The DaShenLin Pharmaceutical Group Co Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2018
1.89 B CNY
Jan 1, 2019
2.06 B CNY
Jan 1, 2020
2.68 B CNY
Jan 1, 2021
3.63 B CNY
Jan 1, 2022
3.87 B CNY
Jan 1, 2023
4.18 B CNY
Jan 1, 2024
4.13 B CNY
Jan 1, 2025
4.14 B CNY
The DaShenLin Pharmaceutical Group Co Inventory history
YEARInventoryYoY
4.14 BCNY+0.32%
4.13 BCNY-1.27%
4.18 BCNY+7.97%
3.87 BCNY+6.68%
3.63 BCNY+35.33%
2.68 BCNY+30.53%
2.06 BCNY+8.96%
1.89 BCNY+9.87%
1.72 BCNY+31.56%
1.30 BCNY+29.18%
1.01 BCNY+33.63%
755.85 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

DaShenLin Pharmaceutical Group Co Stock analysis

What does DaShenLin Pharmaceutical Group Co do? DaShenLin Pharmaceutical Group Co Ltd generates revenue through the retail and wholesale of pharmaceutical products, including Chinese and Western medicine, ginseng nourishing herbs, Chinese medicine pieces, health products, and medical apparatus. The company operates primarily within the domestic market, serving customers who purchase these healthcare commodities directly or through its retail channels. Its business model relies on direct sales and retailing as key revenue streams, targeting consumers and businesses seeking pharmaceutical and health-related products. The firm's product portfolio encompasses a wide range of healthcare items, from traditional Chinese medicine to modern medical devices, all sold under its own brand within China's domestic market. With a focus on both direct sales and retail distribution, DaShenLin Pharmaceutical Group Co Ltd caters to a diverse customer base that includes individual consumers and healthcare institutions requiring medical supplies and health products. DaShenLin Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DaShenLin Pharmaceutical Group Co stock

Inventory of DaShenLin Pharmaceutical Group Co is 4.14 B CNY in 2025.

Inventory of DaShenLin Pharmaceutical Group Co changed from 4.13 B CNY to 4.14 B CNY, representing a 0.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Inventory DaShenLin Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's DaShenLin Pharmaceutical Group Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — DaShenLin Pharmaceutical Group Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — DaShenLin Pharmaceutical Group Co